Survodutide (BI 456906) is an investigational once-weekly injection from Boehringer Ingelheim that acts on glucagon and GLP-1 receptors. It is investigational and not FDA approved.
Also known as: BI 456906.
There is no approved survodutide product. Powder vials are usually labeled 10 mg.
Water and syringe-unit charts by vial size: 10 mg
Here is the math for a 10 mg vial mixed with 2 mL of bacteriostatic water, drawing 2.4 mg with a U-100 insulin syringe (1 mL = 100 units).
10 mg ÷ 2 mL = 5 mg/mL2.4 mg ÷ 5 mg/mL = 0.48 mL0.48 mL × 100 = 48 units| Amount | Volume | U-100 syringe |
|---|---|---|
| 1.2 mg | 0.24 mL | 24 units |
| 2.4 mg | 0.48 mL | 48 units |
| 4.8 mg | 0.96 mL | 96 units |
Adding more water doesn't change how much survodutide is in the vial. It only spreads it over more liquid, so each draw is bigger and easier to read.
| Water added | Concentration | Volume | U-100 syringe |
|---|---|---|---|
| 1 mL | 10 mg/mL | 0.24 mL | 24 units |
| 2 mL | 5 mg/mL | 0.48 mL | 48 units |
| 3 mL | 3.33 mg/mL | 0.72 mL | 72 units |
For any other vial size or amount, the free peptide reconstitution calculator works backwards from the amount you want and suggests a water volume that lands on a clean syringe mark.
In the phase 2 obesity trial (le Roux, Lancet Diabetes Endocrinol 2024; 387 adults without diabetes, 46 weeks), people took 0.6, 2.4, 3.6 or 4.8 mg once weekly or placebo, with 20 weeks of dose escalation. Mean weight change at week 46 ranged from −6.2% on 0.6 mg to −14.9% on 4.8 mg, versus −2.8% on placebo.
In the phase 3 SYNCHRONIZE-1 trial (NEJM 2026; 725 adults with obesity and no diabetes, 76 weeks), doses were stepped up to 3.6 mg or 6.0 mg once weekly. Mean weight change was −12.2% and −13.0%, versus −5.4% on placebo. Gastrointestinal side effects occurred in 80.9% and 89.7% of people on survodutide, versus 47.9% on placebo. SYNCHRONIZE-2 tested the drug in adults with obesity and type 2 diabetes.
We could not open a primary human pharmacokinetic paper for survodutide, so we do not list a half-life or time to peak here.